# BL-8040 Addition to Consolidation Therapy in AML Patients

> **NCT02502968** · PHASE2 · UNKNOWN · sponsor: **Dr. Petra Tschanter** · enrollment: 194 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** BL-8040
- **DRUG:** Placebo (for BL-8040)

## Key facts

- **NCT ID:** NCT02502968
- **Lead sponsor:** Dr. Petra Tschanter
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-09
- **Primary completion:** 2018-07
- **Final completion:** —
- **Target enrollment:** 194 (ESTIMATED)
- **Last updated:** 2015-09-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02502968

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02502968, "BL-8040 Addition to Consolidation Therapy in AML Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02502968. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*